Subsidy Information and Financing Scheme MSHLCladribine Injection 10 mg/5 mL, 10 mg/10 mL Treatment of hairy cell leukaemia.
Drug Guidance for Subsidy 04/01/2022 Disease-modifying therapies for treating multiple sclerosis The Ministry of Health’s Drug Advisory Committee has recommended: Fingolimod 0.25 mg and 0.5 ... See all × 04/01/2022 Disease-modifying therapies for treating multiple sclerosis The Ministry of Health’s Drug Advisory Committee has recommended: Fingolimod 0.25 mg and 0.5 mg capsules for treating adults and children with relapsing-remitting multiple sclerosis, and Siponimod 0.25 mg and 2 mg tablets for treating adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity. Subsidy status RFingolimod 0.25 mg and 0.5 mg capsules and siponimod 0.25 mg and 2 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. NRMAF assistance does not apply to any formulations or strengths of alemtuzumab, cladribine, dimethyl fumarate, interferon beta-1a, natalizumab, ofatumumab or teriflunomide for treating adults or children with any form of multiple sclerosis.
Post Marketing Information DHCPL 16/02/2022 Mavenclad® (cladribine) – risk of serious liver injury and recommendations for liver function monitoring
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Injection 10 mg/10 mL National University Hospital Singapore General Hospital Tablet 10 mg National University Hospital